Cogent Biosciences Inc (COGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -255,859 | -192,410 | -140,241 | -72,273 | -74,808 |
| Depreciation Amortization | -5,169 | -2,903 | -796 | 147 | 720 |
| Accounts receivable | N/A | N/A | N/A | N/A | 2,000 |
| Accounts payable and accrued liabilities | 1,358 | 4,813 | 2,359 | 2,751 | -2,451 |
| Other Working Capital | 11,596 | 11,442 | 751 | 176 | -5,986 |
| Other Operating Activity | 40,283 | 25,434 | 19,289 | 10,436 | 44,675 |
| Operating Cash Flow | $-207,791 | $-153,624 | $-118,638 | $-58,763 | $-35,850 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -573 | -2,796 | -6,863 | -1,719 | 8,420 |
| Purchase Of Investment | -255,603 | -348,803 | -177,855 | N/A | N/A |
| Sale Of Investment | 294,452 | 253,775 | 60,000 | N/A | N/A |
| Investing Cash Flow | $38,276 | $-97,824 | $-124,718 | $-1,719 | $8,420 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 214,451 | 163,536 | 163,558 | 38,061 | 133,289 |
| Other Financing Activity | 0 | 0 | 0 | -85 | 98,907 |
| Financing Cash Flow | $214,451 | $163,536 | $163,558 | $37,976 | $232,196 |
| Beginning Cash Position | 53,229 | 141,141 | 220,939 | 243,445 | 38,679 |
| End Cash Position | 98,165 | 53,229 | 141,141 | 220,939 | 243,445 |
| Net Cash Flow | $44,936 | $-87,912 | $-79,798 | $-22,506 | $204,766 |
| Free Cash Flow | |||||
| Operating Cash Flow | -207,791 | -153,624 | -118,638 | -58,763 | -35,850 |
| Capital Expenditure | -573 | -2,796 | -6,863 | -1,719 | N/A |
| Free Cash Flow | -208,364 | -156,420 | -125,501 | -60,482 | -35,850 |